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Tumor suppressor silencingReversion-inducing cysteine-rich protein with Kazal motifs (RECK) is a tumor suppressor and the
suppression of RECK is induced by Ras or Her-2/neu oncogenes. However, regulation of RECK under hypoxic
microenvironment is largely unknown. Here, we identiﬁed that hypoxia signiﬁcantly downregulates RECK
mRNA and protein expression using semiquantitative RT-PCR, real-time RT-PCR and western blot analysis.
This repression was reversed by the HDAC inhibitor, trichostatin A (TSA) and HIF-1 inhibitor, YC-1. Hypoxia-
induced downregulation of RECK was abolished by knockdown of HDAC1 and HIF-1α with respective small
interfering RNAs (siRNAs), whereas overexpression of HDAC1 and HIF-1α suppressed RECK expression
similar to the level under hypoxic conditions. Transfection of a deletion mutant of the second reverse HRE
(rHRE2, −2345 to −2333) site of RECK promoter completely removed RECK suppression under hypoxia,
indicating that the rHRE2 site is responsible for the inhibition of RECK. Chromatin immunoprecipitation and
DNA afﬁnity precipitation assays demonstrated that HDAC1 and HIF-1α were recruited to the rHRE2 region
of RECK promoter under hypoxic conditions, but the treatment of TSA or YC-1 inhibited their binding to the
rHRE2 site. Moreover, TSA and YC-1 inhibited hypoxia-induced cancer cell migration, invasion and MMPs
secretion. Taken together, we can conclude that hypoxia induces RECK downregulation through the
recruitment of HDAC1 and HIF-1α to the rHRE2 site in the promoter and the inhibition of hypoxic RECK
silencing would be a therapeutic and preventive target for early tumorigenesis.otechnology, College of Natural
1, Republic of Korea. Tel.: +82
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Hypoxia often occurs in a solid tumor because normal vasculature in
tissues can only support tumor growthwithin a diameter of ~2 mm [1].
Hypoxia activates the transcription factor, hypoxia-inducible factor
(HIF), to regulate downstreamtarget genes, such as vascular endothelial
growth factor (VEGF) and the glycolytic enzymes. This stimulates the
cell to increase oxygen availability or to adjust intracellularmetabolism,
and thus cell survival is improved [2]. HIF-1 consists of HIF-1α and a
constitutively expressed aryl hydrocarbon receptor nuclear translocator
known as HIF-1β [3] and binds to the consensus hypoxia-responsive
element (HRE) in the target gene promoter region. The HRE in HIF-1
target genes consists of the core sequence 5′-RCGTG-3′ [4]. Microarray
experiments indicate that far more than 200 HIF target genes might
exist, but not all of those genes are likely to be directly regulated by an
HRE in their regulatory regions [5]. A single core HRE is necessary but
not sufﬁcient for efﬁcient gene activation in response to hypoxia [6–8].
Although the core HRE is the minimal DNA sequence required forinteractionwithHIF, a fully functional HRE usually contains neighboring
DNAbinding sites for additional transcription factors [5]. Several reports
show that HIF-1α occasionally acts as a transcriptional repressor for
certain genes, such as leukemia inhibitory factor receptor (LIFR),
peroxisome proliferator activated receptor (PPAR)α, andα-fetoprotein
by directly binding to speciﬁc HREs on the antisense strand, known as
reverse HREs (rHRE), under hypoxic conditions [9–11].
The reversion-inducing cysteine-rich protein with Kazal motifs
(RECK) gene was isolated as a transformation suppressor gene using
an expression cloning strategy in a v-Ki-Ras-transformedNIH/3T3 cell
line [12]. This gene encodes a membrane glycoprotein that may
inhibit tumor metastasis and angiogenesis by negatively regulating
MMP activity [13,14]. The RECK gene is widely expressed in normal
tissues, while its expression is downregulated in several tumor cell
lines and oncogene-transformed ﬁbroblasts [15–17]. These reports
suggest that the RECK gene is a common negative target for oncogenic
signals and that its downregulation is a step in the pathway towards
malignant conversion. RECK expression is inhibited via a number of
different pathways acting on the Sp1 promoter site of the RECK gene,
such as oncogenic Ras [18]. Her-2/neu also recruits histone
deacetylase (HDAC) to Sp1 proteins, and this combination represses
expression of the RECK gene by binding to the promoter region [19].
This process of inhibition can be achieved either through direct
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the ERK signaling pathway, which then increases the afﬁnity of HDAC
protein binding to the Sp1 region [20].
Aberrant gene silencing is a common phenomenon inmany types of
cancers. It has been reported that hypoxia attenuates the expression of a
variety of tumor suppressor genes, such as p53, pVHL, MLH1, BRCA1,
BRCA2, and RUNX3, in normal and cancer cells [21–24]. p53, pVHL and
RUNX3 are downregulated by increased activity of HDACs, and addition
of the HDAC inhibitor trichostatin A (TSA) reduced the amount of
hypoxia-induced repression of the genes [21,24,25]. These results
indicate that increased HDAC activity is involved in the silence of tumor
suppressors under hypoxic conditions. The involvement of histone
methyltransferase (HMT) is also reported to be involved in the silencing
of RUNX3 [24] andMLH1under hypoxia [22,23]. Treatmentwith 5-Aza-
2′-deoxycytidine (5-Aza), a DNA methyltransferase inhibitor that is
known to inhibit histone methylation, restores RUNX3 [24] and MLH1
[22] silencing by hypoxia, even though RUNX3 DNA promoter
methylation is not changed under hypoxic conditions. However, it still
has yet to bedeterminedwhether or not the hypoxicmicroenvironment
can downregulate the expression of RECK.
In this study, we determined that hypoxia suppressed RECK
expression and that HIF-1α and HDAC1 are involved in hypoxia-
induced RECK repression. The transcriptional activity, the expression,
and the promoter binding activity of RECK were determined under
hypoxic conditions. These were further examined under several
different contexts, including treatmentwith HDAC or HIF-1α inhibitors,
knockdown of HDAC1 or HIF-1α under hypoxia, and overexpression of
HDAC1 or HIF-1α under normoxia. Our data suggest that repression of
RECK under hypoxic conditions is mediated by HDAC1 and HIF-1,
through their binding to rHRE sites located at−2345 to−2333 in the
proximal promoter. Furthermore, hypoxia-induced migration and
invasion of breast cancer cells and activity of MMPs were signiﬁcantly
inhibitedby the treatmentwith TSA andYC-1. These results suggest that
hypoxic silencing of RECK, a tumor suppressor could be prevented by
inhibition of HDAC and HIF-1α activity in early stage of tumorigenesis.
2. Materials and methods
2.1. Cell culture and hypoxia exposure
Human embryonic kidney epithelial cells, HEK293, and mouse
kidney epithelial cells, TCMK-1, were obtained from the American
Type Culture Collection. Cells weremaintained in Dulbecco's Modiﬁed
Eagles Medium (DMEM) (Hyclone, Logan, UT) supplemented with
10% fetal bovine serum (FBS) (Hyclone, Logan, UT) and 1% antibiotics.
H-Ras MCF10A cells were cultured in DMEM/F12 supplemented with
5% FBS, 0.5 μl/ml hydrocortisone, 10 μl/ml insulin, 20 nl/ml EGF (R&D
systems, Wiesbaden, Germany), 0.1 μl/ml cholera toxin (Sigma, St
Louis, MO), 100U/ml penicillin–streptomycin, 2 mM L-glutamine and
0.5 μl/ml fungizone (Invitrogen, Gaithersburg, MD). Hypoxic cham-
bers (Thermo Scientiﬁc, MA, USA and Astec, Japan) were used for
maintaining either hypoxic (1% O2 or 0.1% O2, 5% CO2, and N2 balance)
or normoxic (21% O2, 5% CO2) conditions at 37 °C.
2.2. Semiquantitative and real-time RT-PCR analysis
Total RNA was extracted from cells after normoxic or hypoxic
exposure using the TRIzol Reagent (Invitrogen, Carlsbad, CA). RECK
expression was examined by semiquantitative RT-PCR. β-actin was
used as an internal control. The conditions for PCR were 30 cycles of
denaturation (94 °C/1 min), annealing (60 °C/1 min), and extension
(72 °C/1 min) with a ﬁnal extension step (72 °C/10 min). Primer
sequences are as follows: for RECK, forward, 5′-CCTCAGTGAGCA-
CAGTTCAGA-3′; reverse, 5′-GCAGCACACACACTGCTGTA-3′; for
HDAC1 forward, 5′-CTGCTTAGTAGCTTTGGA-3′, reverse, 5′-TATCT-
CAAAAAGGAAACTAGACT-3′; for HIF-1α, forward, 5′-CAGAAGATA-CAAGTAGCCTC-3′; reverse: 5′-GGCCCGGTGCAGCACCACCA-3′, for β-
actin, forward, 5′-GACTACCTCATGAAGATC-3′, reverse, 5′-CTGCT
GGAATACTGTAACTG-3′. PCR products were separated on a 1.5%
agarose gel in 0.5× TBE buffer, stained with ethidium bromide, and
visualized under UV light.
Quantitative real-time RT-PCR assays were performed on an ABI
PRISM 7300 HT (Applied Biosystems) with SYBR-green premix Ex Tag
(Takara, Japan). Real-time PCR ampliﬁcation was carried out as
previously described [24]. The sequences for RECK were: forward, 5′-
CCTGCATTGCTCGCTGTGTG-3′, reverse, 5′-CCTGTGGTTTGGGTATG-
CACCTT-3′, and for β-actin: forward, 5′-TTGCCGACAGGATGCAGAA-3′,
reverse, 5′-GCCGATCCACACGGAGTACT-3′. Relative mRNA expression
was normalized to the expression level of β-actin.
2.3. Western blot analysis
Cells were lysed in a lysis buffer. Equal amounts of protein were
subjected to 10% SDS-PAGE and transferred to a nitrocellulose
membrane (Whatman, England). Blocking was performed with 5%
(w/v) nonfat-dry milk tris-buffered saline (TBS) containing 0.1%
Tween-20, and then the blots were incubated with the speciﬁc
antibodies mouse anti-human HIF-1α (BD Biosciences, San Diego,
CA), mouse anti-human RECK (R&D systems), rabbit anti-human
HDAC1 (Cell Signaling, Danver, MA) or mouse anti-human β-actin
(Santa Cruz Biotechnology, Santa Cruz, CA). Secondary antibodies
conjugated with horseradish peroxidase (Santa Cruz) were used and
immunoreactive proteins were detected using the Super Signal West
Pico Chemiluminescent Substrate (Pierce, Woburn, MA).
2.4. Luciferase activity assay
HEK293 cells were plated onto 35 mm dishes at a density of
250,000 cells/well and grown overnight. Cells were cotransfected with
mouse full-length RECK promoter luciferase vector (pGL3) and pCMV-
β-galactosidase plasmid using the WelFect-EX transfection reagent
(WelGene, Daegu, Korea) according to the manufacturer's protocol.
After cells were incubated under normoxia or hypoxia conditions for
24 h, luciferase activity was analyzed using an assay kit (Promega,
Madison, WI) and luminometer (Turner Designs, Sunnyvale, CA). The
relative luciferase activity was normalized using the transfection
efﬁciency as determined by β-galactosidase activity.
2.5. Knockdown of HDAC1, HIF-1α and RECK
HEK293 cells were transfected with double stranded RNA using a
HiPerfect Transfection reagent (Qiagen). After placed under normoxia
or hypoxia for 24 h, cells were harvested for the detection of gene
expression by semiquantitative RT-PCR. Sequences of siRNA for HIF-
1α were 5′-GUUGCCACUUCCGACUAAUdTdT-3′ (Samchully Pharm
Co., Seoul, Korea), for HDAC1, 5′-CCCGGAGGACCAUCUGUUAdTdT-3′
(Qiagen, Valencia, CA) and for RECK, 5′-CAGATTGAAGCCTGCAATAAA-3′
(Bioneer, Daejeon, Korea).
2.6. Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed as previously described [24]. Brieﬂy,
TCMK-1 cells were ﬁxed and then cell lysates were sonicated on ice.
After the lysateswere treatedwith anti-HIF-1α or anti-HDAC1 or anti-
HDAC7 antibody (Santa Cruz Biotechnology) overnight at 4 °C,
immune complexes were collected on a salmon sperm DNA/protein
G agarose slurry and were then extracted from the beads with 1% SDS
and 0.1 M NaHCO3. The DNA was recovered and subjected to PCR
ampliﬁcation using the primers speciﬁc for the −2402 to −2215
region, which contains the rHRE2 site of the RECK promoter. The
primers used were as follows: sense, 5′-ACTTCTGGTGCTGTGCTGC-3′;
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the PCR product was 187 bp.
2.7. DNA afﬁnity precipitation assay (DAPA)
The binding assay was performed by mixing nuclear extract with a
biotinylated DNAprobe in the−2333 to−2345 upstream region of the
translational start site of RECK gene, and the DNA–protein complexes
were precipitated by streptavidin-coated beads. The binding proteins
were eluted by loading buffer and separated by SDS-PAGE, followed by
western blot analysis with speciﬁc antibodies for HDAC1 and HIF-1α.
Biotinylated reverse HRE sequences were 5′-biotin-GCAAGGCCACGTG-
GAGGACACGGG-3′ and 5′-biotin-CCCGTGTCCTCCACGTGGCCTTGC-3′.
2.8. Wound migration and transwell invasion assays
Wound migration assay with H-ras MCF10A cells was performed as
follows; cells were plated on 35 mmdishes. At 90% conﬂuency, the cells
were marked an injury line and wounded 1 mm in width. Plates were
rinsed with serum-free medium to remove cellular debris. Fresh
medium with 10% serum and mitomycin C (2 μg/ml) was then added.
Cells were allowed to migrate for 24 h and rinsed with serum-free
medium, and photographs were taken through an inverted microscope
(×40). The number of cells that moved beyond the injury line was
counted. Independent experiment was performed more than three
times.
For the cell invasion assay, the upper surface of the membrane was
coatedwithMatrigel (BD Biosciences, SanDiego, CA). The transwell was
placed in a well with DMEM/F12 containing 5% FBS. The cells were
seeded into the upper chamber in serum-free media in the presence or
absence of TSA or YC-1 (Merck Biosciences, Darmstadt, Germany). After
incubationunder normoxia orhypoxia for 24 h, the cellswereﬁxedwith
formaldehyde and removed from the top surface of the chamber. The
cells on the lower surface of the ﬁlter were stained with hematoxylin
and eosin (Sigma, St Louis, MO). The cells that invaded to lower side of
the ﬁlter were observed using a light microscope and counted.
2.9. Gelatin zymography
After the cells were cultured in serum-free medium for 24 h, the
conditioned medium (CM) was collected and centrifuged at 3000 rpm
for 10 min to remove the cell debris. The CMwas electrophoresed in 10%
SDS-PAGE gels containing 1 mg/ml gelatin under non-reducing
condition. After electrophoresis, the gels were incubated overnight in
the zymography reaction buffer (50 mM Tris pH7.8, 10 mM CaCl2,
150 mM NaCl, 2 μM ZnCl2) at 37 °C. The gels were stained with a 0.5%
Coomassie Brilliant Blue F-250 solution containing 10% acetic acid and
20%methanol and destainedwith a 10% acetic acid solution. The areas of
gelatinase activityweredetected as a clear zoneagainst the blue-stained
gelatin background.
2.10. Statistical analysis
The ANOVA test was used to assess the signiﬁcance of the
differences among the experimental groups. The results are repre-
sented as means±standard deviation (S.D.).
3. Results
3.1. Hypoxia downregulates RECK expression in kidney epithelial cells
To investigate whether hypoxia regulates RECK expression,
normal human kidney epithelial (HEK293) cells were cultured
under 21% (N) or 0.1% O2 (H) concentration conditions. Semiquan-
titative RT-PCR and western blot analysis demonstrated that the
relative mRNA expression of RECK protein expression was signiﬁ-cantly downregulated under hypoxic conditions in a time-dependent
manner (Fig. 1A). To conﬁrm this result, quantitative real-time RT-
PCR analysis was performed using different primer sets. RECK mRNA
expression was signiﬁcantly inhibited after 4 h. Hypoxic exposure for
24 h decreased expression 3.5-fold when compared to the levels
under normoxic exposure, suggesting that hypoxia clearly down-
regulates RECK expression (Fig. 1B). Furthermore, By the RECK
promoter reporter assay, we conﬁrmed that hypoxia signiﬁcantly
inhibited RECK gene expression in a time-dependent manner
(Fig. 1C). Next, we tested the effect of a hypoxia mimetic compound,
desferrioxamine (Dfx) on the expression of RECK. As shown in Fig. 1D,
Dfx signiﬁcantly downregulated mRNA and protein level of RECK to
the same degree as hypoxic conditions. These results suggest that
hypoxia suppresses RECK expression at the transcriptional level.
3.2. HDAC1 and HIF-1α are involved in RECK suppression
Upregulation of HDAC activity contributes to tumorigenesis through
the promotion of inappropriate gene repression, particularly of tumor
suppressor genes under hypoxic conditions [21,24]. Under hypoxic
conditions, HDAC activity and expression are markedly increased
[21,24]. HIF-1α is a major transcription factor in hypoxia to regulate
hypoxia-inducible genes. Inorder to determine ifHDAC1andHIF-1α are
involved in the hypoxia-induced downregulation of RECK, we treated
the cellswith inhibitors ofHDAC1andHIF-1αunderhypoxic conditions.
The treatment of HEK293 cells with trichostatin A (TSA), an HDAC
inhibitor, and YC-1, a HIF-1α inhibitor restored RECKmRNA expression
under hypoxic conditions by the real-time RT-PCR (Fig. 2A). TSA
restoredRECK expression into a levelmore thannormal controlwhereas
under hypoxic conditions restoration of RECK by YC-1 was less than
normoxic control cells (Fig. 2A). Our interestwas to ﬁndoutmechanism
of RECK downregulation under hypoxic conditions, we performed
further experiments to the exclusion of the involvement of HDAC1 or
HIF-1α under normoxic conditions. When we performed the promoter
luciferase assay, RECK reporter activity was decreased by hypoxia but
again restored to a level greater than that of the control by TSA and YC-1
(Fig. 2B). From these results, we can suggest that HDAC1 and HIF-1α
might be involved in hypoxia-induced RECK suppression and even in
normoxic conditions RECK gene might be partly suppressed by HDAC1
and HIF-1α.
Because YC-1 inhibits HIF-2α stability [26], we next investigated
whether HDAC1 and HIF-1α or HIF-2α are involved in the down-
regulation of RECK expression, we transfected cells with full-length
HDAC1 and/or GFP-HIF-1α and/or Flag-HIF-2α under normoxic
conditions and performed both semiquantitative RT-PCR. The over-
expression of HIF-1α markedly decreased expression of RECK mRNA
but that of HIF-2α did not (Fig. 2C) and thus we excluded a possibility
of HIF-2α involvement in RECΚ suppression under hypoxic condi-
tions. Next, the RECK promoter reporter activity was performed to
conﬁrm the RT-PCR data. RECK mRNA level was signiﬁcantly down-
regulated in mock-transfectants under hypoxic conditions. Even
HDAC1- or HIF-1α-transfectants also suppressed RECK efﬁciently,
double transfectants with HDAC1 and HIF-1α showed a complete
silencing of RECK mRNA, indicating that HIF-1α and HDAC1
collaborate to suppress RECK expression (Fig. 2D). Taken together,
these results suggest that both HDAC1 and HIF-1α play a critical role
in the downregulation of RECK expression.
3.3. HDAC1 and HIF-1α are crucial for RECK suppression by hypoxia
To clarify if HDAC1 and HIF-1α are really involved in the hypoxia-
induced downregulation of RECK, we adopted a siRNA knockdown
strategy for HDAC1 and HIF-1α. Knockdown of HDAC1 resulted in an
increase in the expression level of RECK mRNA under normoxia or
hypoxia (Fig. 3A). Hypoxia increased HDAC1 but decreased the mRNA
and protein levels of RECK. Thus, RECK expression under hypoxic
Fig. 1. Downregulation of RECK under hypoxic conditions. (A) HEK293 cells were exposed to hypoxia for the indicated times and mRNA levels or protein levels were determined by
RT-PCR and western blot analysis. Beta-actin was used for the internal loading control. (B) Real-time RT-PCR analysis was also performed with HEK 293 cells incubated under
hypoxic conditions for 4, 16 and 24 h. Relative mRNA expression level after normalized with β-actin expression level was graphed between normal control and hypoxic cells.
*pb0.01 vs. normoxia (N), **pb0.01 vs. 4, 16 h of hypoxia and normoxia. (C) After transfection with the RECK promoter–luciferase reporter plasmid, mouse kidney epithelial TCMK
cells were exposed to normoxia or hypoxia for the indicated times. Luciferase activity was assayed and relative activity was calculated compared to β-gal activity. Signiﬁcant
differences from the normoxia (N) were noted as *pb0.01, and from 4, 8 h of hypoxia as well as the normoxia (N) as **pb0.01. (D) HEK293 cells were treated with desferrioxamine
(dfx, 160 μM) or exposed to hypoxic conditions for 24 h. RT-PCR or western blot was performed to check the expression pattern of RECK. Beta-actin was used for the internal loading
control.
Fig. 2.HDAC and HIF-1α inhibitors restore the RECK expression under hypoxic conditions. (A) HEK 293 cells were incubated under normoxic or hypoxic conditions in the presence or
absence of an HDAC inhibitor, TSA or a HIF-1α inhibitor, YC-1, for 24 h. Quantitative real-time RT-PCR was performed and the expression of RECK mRNA was analyzed and graphed
after normalized with β-actin expression. Signiﬁcant differences from normoxia (N) were noted as *pb0.01, and from hypoxic control were noted as **pb0.01, (B) HEK293 cells were
transfected with a RECK promoter–luciferase reporter plasmid, and, one day later, cells were incubated under normoxia or hypoxia in the presence or absence of TSA or YC-1 for 24 h.
RECK promoter activity was determined. Relative luciferase activity was determined by normalization with β-galactosidase activity. Signiﬁcant differences from the normoxia (N)
were noted as *pb0.01, from the hypoxic control were noted as **pb0.01, and from H+TSA were noted as #pb0.01. (C) HEK293 cells were transfected with an expression vector for
GFP-HIF-1α, pcDNAHIF-2α and/or pcDNAHDAC1 full-length or pcDNA alone. Forty-eight hours after transfection, the cells were collected and compared to the hypoxic samples (for
24 h) for RECK mRNA expression by RT-PCR. β-actin was used as an internal control. (D) HEK293 cells were transfected with RECK promoter–luciferase plasmid and HDAC1 and/or
GFP-HIF-1α full-length vectors. Hypoxic cells were incubated under hypoxic conditions for 24 h after 24 h of the transfection. Signiﬁcant differences from the normoxic control cells
were noted as *pb0.01, and signiﬁcant differences from the hypoxic control group were noted as **pb0.01.
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Fig. 3. Knockdown of HDAC1 and HIF-1α with siRNAs recovers RECK silencing.
(A) HEK293 cells were transfected with scrambled or HDAC1 siRNA. 24 h after
transfection, the cells were incubated under normoxia or hypoxia for 24 h, and then the
expression of RECK and HDAC1 was determined by RT-PCR and western blot. (B) HEK293
cells were transfected with scrambled or HIF-1α-speciﬁc siRNA and the expression was
again determined as described in A. Signiﬁcant differences from the normoxic control cells
were noted as *pb0.01.
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Repression of endogenous HIF-1α by siRNA in HEK293 cells under
hypoxic conditions showed thatmRNAexpression of RECKwas restored
(Fig. 3B). Taken together, the results from these experiments of
overexpression or knockdown of HDAC1 and HIF-1α indicate that
HDAC1 and HIF-1α are crucial for the suppression of RECK under
hypoxic conditions.
3.4. Downregulation of RECK by hypoxia through an rHRE site
To investigate the mechanisms underlying HDAC1- and HIF-1α-
mediated suppression of RECK, we performed a promoter database
analysis for RECK. The RECK promoter region possesses two rHREs
(i.e., antisense sequence), one reverse Sp1 site (rSP1), and two
forward Sp1 sites (Fig. 4A). To determine which binding sites are
responsible for the hypoxic repression of RECK, we constructed serial
deletion mutants of the RECK promoter and measured the promoterFig. 4. Hypoxia represses RECK via the second reverse HRE HIF binding site. (A) Schematic
serial deletion mutant of promoter driven by the expression of luciferase reporter gene. (B) H
RECK promoter activity was studied at 24 h after hypoxia as described inMaterials andmetho
(N). H, hypoxia.activity under hypoxic conditions. Exposure to hypoxia signiﬁcantly
decreased luciferase activity by 2.2 to 2.5 fold in cell extracts
transfected with the p(−2559~)-Luc plasmid, in which the ﬁrst
rHRE sequence (rHRE1) is deleted (Fig. 4B). However, the deletions
for the second upstream rHRE (rHRE2) site completely blocked the
suppression of the reporter activity of RECK under hypoxic conditions
(Fig. 4B, p(−294~)-Luc and p(−154~)-Luc). These ﬁndings indicated
that repression of RECK promoter activity by hypoxia largely depends
on the −2559 to −294 sites, which contain the rHRE2 site.3.5. Hypoxia increases the recruitment of HDAC1 and HIF-1α on the
reverse HRE site
Since our results showed that HIF-1α and HDAC1 may be involved
in RECK downregulation under hypoxic conditions (Figs. 2, 3), we
next investigated whether HIF-1α and HDAC1 are recruited to the
RECK promoter using DNA precipitation (DAPA) and ChIP assays with
sequences containing rHRE2. DAPA analysis showed an increase in
nuclear HDAC1 and HIF-1α in TCMK-1 cells under hypoxia (Fig. 5A),
showing that binding of HDAC1 and HIF-1α to a DNA probe that
contains rHRE2 site of the RECK promoter was obviously enhanced
under hypoxic conditions. The binding of HDAC1 and HIF-1α to the
promoter sequence was decreased by treatment with either TSA or
YC-1 under hypoxic conditions (Fig. 5A). These results suggest that
the rHRE2 site, located at −2345 to −2333, is required for the
hypoxic downregulation of RECK by HDAC1 and HIF-1α. To conﬁrm
these results, a ChIP assay was performed using primers harboring the
RECK promoter rHRE2 site under hypoxic conditions. When immu-
noprecipitated with the anti-HIF-1α antibody, hypoxia increased the
binding activity of HIF-1α to the rHRE2 site of the RECK promoter
region. Also, HDAC1 binding to the rHRE2 site of the RECK promoter
was signiﬁcantly increased under hypoxia, whereas the acetylated
histone H3 in the RECK promoter region was slightly decreased
(Fig. 5B). As a positive control, binding of HDAC7 to the rHRE2 site of
RECK promoter was included because HDAC7 binds to HIF-1α under
normoxic or hypoxic conditions [27] (Fig. 5B). Collectively, these data
suggest that hypoxia induces the recruitment of HDAC1 and HIF-1α to
rHRE2 site on the RECK promoter to suppress RECK gene expression.diagram of transcriptional factor binding motifs in full-sequence RECK promoter and a
EK293 cells were transfected with full-length RECK promoter or deletion mutants, and
ds. Signiﬁcant differences were indicated as *pb0.01 compared to the normoxic control
Fig. 5. HDAC1 and HIF-1α bind to the second HRE region in RECK promoter. (A) DAPA assay was performed with the biotinylated DNA probe harboring the second HRE sequences of
RECK promoter and anti-HIF-1α and anti-HDAC1 antibodies to measure the binding of HIF-1α and HDAC1 to the RECK promoter region. The DNA–protein complex was precipitated
by streptavidin-coated beads, and a western blot was performedwith each antibody. The protein level in the nuclear fraction was also measured to determine the relative expression
level. PCNA was detected for the internal control of the nuclear fraction. Right panel is quantitation of each band in the DAPA assay data relative to PCNA band was graphed from the
results of three different experiments. Signiﬁcant differences were indicated as *pb0.01 compared to the normoxic control (N) and as **pb0.01 compared to the hypoxia control (H).
(B) The ChIP assay in TCMK-1 cells was performed with anti-HIF-1α, anti-HDAC1, anti-HDAC7, anti-acetyl histone H3, and IgG antibodies. PCR ampliﬁcation using the primers
covering the second HRE sequences of the RECK promoter. Right panel is quantitation of each band in the ChIP assay data relative to the input control was graphed from the results of
three different experiments. Signiﬁcant differences were indicated as *pb0.01 compared to the normoxic control.
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cell migration, invasion and MMP activity
Because RECK is an inhibitor of MMPs, hypoxic silencing of RECK
by HDAC1 and HIF-1α would inﬂuence cancer cell migration. To
investigate whether inhibition of HDAC1 and HIF-1α under hypoxic
conditions prevents cancer cell migration and invasion, we performed
wound migration and transwell invasion assays under normoxic or
hypoxic conditions. Hypoxia signiﬁcantly increased migration and
invasion of H-ras MCF10A breast cancer cells compared to normoxic
control cells (Fig. 6A, B). Hypoxia downregulated RECK expression
and TSA or YC-1 recovered hypoxia-induced downregulation also in
H-ras MCF10A cells (data not shown). Treatment with TSA and YC-1
signiﬁcantly inhibited the migration and invasion of H-ras MCF10A
cells both under normoxic and hypoxic conditions (Fig. 6A, B). The
results suggest that inhibition of HDAC1 and HIF-1α activity could
prevent hypoxia-induced cancer cell migration and invasion. Conse-
quently, RECK restoration by inhibition of HDAC1 and HIF-1α would
be a good preventive strategy in early tumorigenesis and tumor
progression. To conﬁrm the involvement of RECK in hypoxia-induced
migration and invasion of the cells, we transfected cells with siRECK
or RECK full-length plasmid and performed migration and invasion
assays. Silencing of RECK by siRECK under normoxic conditions
increased migration and invasion to a level similar to that observed in
the hypoxic control cells. Furthermore, RECK overexpression underhypoxic conditions signiﬁcantly inhibited hypoxia-induced migration
and invasion of the cells. Next, we performed a gelatin zymography
assay with the supernatant of the cells used above. The activity of
MMP-2 and MMP-9 was increased by hypoxic stress and silencing of
RECK but the treatment with TSA or YC-1 as well as overexpression of
RECK inhibited the secretion of MMP-2 andMMP-9 to the supernatant
(Fig. 6C). These results suggest that RECK silencing is a crucial
pathway to increase migration and invasion of the cells under hypoxic
conditions through MMPs.4. Discussion
In this study, we demonstrated that RECK expression was down-
regulated by hypoxia. In addition, we showed that RECK suppression
by hypoxia is mediated by HDAC1 and HIF-1α. An rHRE2 site in the
RECK promoter is involved in this suppression under hypoxic
conditions. Here, we focused on hypoxia, a reduction of tissue oxygen
tension, as a microenvironmental stress for the silencing of a tumor
suppressor, RECK. Recently, an increasing number of reports have
demonstrated that hypoxia is highly associated with chronic
inﬂammation [28], acute and chronic vascular diseases, pulmonary
disease, and wound healing processes [29–31], all of which are
premalignant pathological conditions. We hypothesized that the
hypoxia associated with these pathological conditions could silence
Fig. 6. Inhibitors of HDAC and HIF-1α block hypoxia-induced cancer cell migration and invasion. (A) H-ras MCF10A cells were transfected with RECK full-length plasmid (OE) or
siRNA or mock plasmid and plated on 35 mm dish at 3×105 density, and 24 h later wounded 1 mm in width. After cells were treated with mitomycin C (25 μg/ml) for 30 min and
exposed to normoxic (N) or hypoxic (H) conditions for 24 h with or without TSA (330 nM) or YC-1 (10 μM). Dashed lines are injured lines. The number of cells that moved beyond
the wound line was counted in three independent experiments and graphed as fold compared to normoxic control group. (B) Similarly, the invasion of H-RasMCF10A cells through a
Matrigel using a transwell was examined. TSA (330 nM) or YC-1 (10 μM) was added to both sides of the transwell membrane for 24h. The invaded cells were counted and are
graphed below. Signiﬁcant differences were indicated as *pb0.01 compared to the normoxic control, and as #pb0.01 compared to the hypoxia control. (C) A gelatin zymography
assay was performed to analyze the gelatinolytic activity of secreted MMP-2 (72 kDa) and MMP-9 (95 kDa). H-Ras MCF10A cells were transfected with RECK full-length plasmid
(OE) or siRNA or mock plasmid and cultured under normoxic or hypoxic conditions with or without TSA (330 nM) or YC-1 (10 μM) for 24 h. A gelatin zymograph assay was
performed with the supernatant obtained from the cultured cells.
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malignant tumor.
Recent reports indicate that hypoxia attenuates tumor suppressor
genes, such as BNIP3, p53, pVHL, MLH1, BRCA1, BRCA2, and RUNX3 in
cancer and in normal cells [21–24]. Some epigenetic mechanism(s)
appears to be involved in this hypoxia-induced repression of tumor
suppressors. For example, MLH1 is silenced by hypoxia, but an HDAC
inhibitor recovered the repression [22]. p53 and pVHL are also
recovered by an HDAC inhibitor under hypoxic conditions in
hepatoma cells [21]. Our recent ﬁndings also show that RUNX3,
which is silenced in gastric cancer cells by hypoxia, is restored by the
treatment of epigenetic-regulating agents and that the involvement of
HDAC1 and G9a histone methyltransferase (HMT) in the suppression
of RUNX3 occurs at the transcriptional level [24]. Hypoxia clearly
increases HDAC levels [24] and activity [21]. In this study, we showed
that the HDAC inhibitor TSA recovered RECK mRNA expression and
reporter activity (Fig. 2A, B). TSA recovered the hypoxic RECK reporter
activity to a level much higher than that of the normoxic control(Fig. 2B). In addition, HDAC siRNA increased RECK expression level in
normoxic cells (Fig. 3A). The results indicate that the expression level of
the RECK gene is partially suppressed in HEK293 cells by HDAC activity,
even under normoxic conditions. Just as if the RECK gene is down-
regulated in many tumor cell lines [12], RECK expression is also sup-
pressed even in normal epithelial cells, such asHEK 293 cells, because of
the immortalized nature of these cells. Further downregulation under
hypoxic conditions might occur via an increased recruitment of HDAC1
to the rHRE site in theRECKpromoter, andHDAC1 is likely to collaborate
with HIF-1α to suppress the transcription (Fig. 2A). An alternative
mechanism of HDAC involvement in RECK downregulation is that
increased HDAC activity under hypoxic conditions might change the
chromatin structure so that it ismore compact in the promoter region of
RECK. However, both of these could also occur concomitantly.
RECK is silenced in oral squamous carcinoma cells and Ras-
oncogene-transformed cells by the promoter hypermethylation
[32,33]. However, as 5-Aza did not recover the RECK downregulation
under hypoxic conditions, promoter hypermethylation might not be
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(data not shown). Our recent ﬁndings also showed that hypoxia did
not change the methylation pattern in the RUNX3 promoter [24],
suggesting that change of promoter methylation of tumor suppressors
may not be the silencing mechanism for these genes under hypoxic
conditions in our system.
Antisense rHRE sites are responsible for the repression of several
genes, such as α-fetoprotein and LIFR under hypoxia [9–11]. HIF-1α is
induced under hypoxia and directly binds to rHRE sites to suppress
these genes. Our data have provided several lines of experimental
evidence to suggest that the rHRE site in the RECK promoter is involved
in hypoxia-induced RECK suppression. First, RECK promoter activity
was recoveredwhen an rHRE site deletionmutantwas transfected into
cells under hypoxia (Fig. 4B). Second, HIF-1α and HDAC1 bound to the
24 bps DNA probewhich contained the rHRE site of the RECK promoter
(Fig. 5A). Third, the effect of hypoxia on the binding of HIF-1 and
HDAC1 to the rHRE site was decreased when cells were treated with
TSA or YC-1 (Fig. 5A). Based on recent studies reporting that v-Ki-Ras
and Her-2/neu suppress the RECK gene through the recruitment of
HDAC1 to Sp1 binding site with an Sp1 transcriptional factor [18,19],
we can speculate that the antisense rHRE region in the gene promoter
provides the template to recruit HIF-1α and a high amount of HDAC
protein to bind there and inhibit transcriptional progression of the
genes under hypoxic conditions. However, the sense HRE site is also
involved in the inhibition of certain tumor suppressors. MLH1 is re-
pressed indirectly by HIF-1 which uses the sense HRE site in the pro-
moter of DEC1 and DEC2 genes [34]. Moreover, the CCAAT/enhancer
binding protein (C/EBP)-α is downregulated by hypoxia through the
binding of HIF-1 to its sense HRE site [35]. G9a HMT is also involved in
the silencing of MLH1 by hypoxia [36] in the same way as it is in the
RUNX3 silencingby hypoxia [24]. Therefore, several distinct factors and
mechanisms, including the rHRE region in the target promoter site,might
be involved in the silencing of various tumor suppressors by hypoxia.
Taken together, our data indicate that hypoxia-induced RECK
downregulation is mediated by the stabilization and recruitment of
HDAC1 and HIF-1α to the reverse HRE site in the RECK promoter. In
the early stage of tumor development, a hypoxicmicroenvironment in
cells and tissues could be protected by treatment with some drugs for
wound healing, anti-inﬂammation, and anti-vascular angiogenesis. In
addition, destabilizing or inactivating agents acting on HIF-1α and
HDAC1 could be developed to protect against the silencing of tumor
suppressors during the early onset of the tumorigenic process.
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